Surgi Plast in 2026: What Its Clinic Syringes, DRAP Records and Recent Safety Alerts Actually Show
Behind the familiar “Clinic” syringe label is a Pakistani medical-device manufacturer whose regulatory record is more substantial—and more complicated—than a simple Google search suggests.
A syringe brand can look ordinary on a hospital shelf. The manufacturer behind it is another matter. In the case of Surgi Plast, the public record connects a Gadoon Amazai factory in Swabi, Khyber Pakhtunkhwa, with syringes, IV sets, scalp-vein sets, blood-transfusion equipment and needles. At the same time, 2026 brought regulatory scrutiny of specific Clinic auto-disable syringe batches, making verification more important than reputation alone.
The company is also a useful case study in how medical-device information gets distorted online. Older supplier directories repeat large market-share claims, while the company’s current website mixes legitimate product information with obvious template remnants. Against that noise, Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) provides a much firmer documentary trail.
BLUF: Surgi Plast is a Pakistan-based medical-device manufacturer in Gadoon Amazai, Swabi, producing syringes, IV sets, scalp-vein sets and related disposables. Pakistani regulatory records confirm multiple Clinic-branded devices and manufacturing sections, while 2026 public reports identify specific Clinic auto-disable syringe batches subject to regulatory action.
Surgi Plast begins with a factory address, not a celebrity-style corporate story
The clearest identifying detail is geographic.
Surgi Plast’s website gives its address as Plot 78, Road L4, Industrial Estate Gadoon Amazai, District Swabi, Khyber Pakhtunkhwa, Pakistan. DRAP records independently place the manufacturer at the same Gadoon Amazai industrial location. The Swabi Chamber of Commerce has also listed Surgi Plast as a medical-products business at Plot 78 in Gadoon Amazai Industrial Estate.
Quick profile
- Company: Surgi Plast
- Industry: Medical devices and disposable healthcare products
- Country: Pakistan
- Manufacturing location: Gadoon Amazai, District Swabi, Khyber Pakhtunkhwa
- Website-listed categories: Syringes, IV Sets, Scalp Vein Sets
- Primary product brand appearing in DRAP records: Clinic
- DRAP establishment record: ELM-0030
- Registered products include: Clinic syringes, Clinic Blood Transfusion Set and Medi Aqua needles
- 2026 issue: Specific Clinic auto-disable syringe batches were reported as failing reuse-prevention testing
Older commercial directories list 2006 as the company’s establishment year and identify Tariq Mehmood Siddiqui as a contact or managing partner. Those records are useful historical clues, but the company’s own current website does not prominently publish a founding-year history, so 2006 is better treated as a secondary-source establishment date rather than an independently verified corporate anniversary.
The same caution applies to claims that Surgi Plast once controlled 70% to 75% of Pakistan’s local market. That figure appears in older supplier-directory material, including PakBD and EC21, but no recent authoritative market study located for this article substantiates it. A repeated percentage is not the same thing as independently measured market share.
The Clinic label is backed by a surprisingly broad regulatory footprint
Surgi Plast is not represented in Pakistani records by one generic “syringe” entry. DRAP documentation shows multiple specific products and registrations connected with the manufacturer.
A 2023 medical-device registration list records CLINIC Disposable Syringe 20ml/cc with 21G and 22G needles under registration MDMR-000227, issued on February 21, 2023. The same regulatory dataset records Clinic Disposable Syringe 30ml, 50ml and 60ml with 21G and 22G needles as MDMR-000307, issued December 20, 2023, and a Clinic insulin syringe, 1cc, 30-gauge, 5/18-inch (8mm) as MDMR-000308, issued the same day.
The record expanded further in 2025. DRAP lists a Clinic Blood Transfusion Set under registration MDMR-000487, issued March 3, 2025. It also records Medi Aqua 23G x 1-inch needles as MDMR-000489 and Medi Aqua 18G x 1.2-inch needles as MDMR-000491, both associated with Surgi Plast.
DRAP’s 76th Medical Device Board decision also records a Clinic Blood Transfusion Set as a Class B medical device and states that the application was approved because the firm had an IV-set facility.
That matters because it establishes something more precise than “Surgi Plast makes syringes.” The regulatory record shows a manufacturer involved across several disposable injection and infusion-device categories.
The product range shown by Surgi Plast itself
The company’s current website lists:
| Website-listed product | What the site currently states |
|---|---|
| 20ml Luer Lock Tip With Needle | Single-use, non-pyrogenic, sterilized by E.O. gas |
| 10ml Luer Lock Tip With Needle | Single-use, non-pyrogenic, sterilized by E.O. gas |
| 5ml Auto Disable Syringe | Sterilized by E.O. gas |
| 1ml Luer Lock Tip With Needle | Single-use, non-pyrogenic, sterilized by E.O. gas |
| 3ml Auto Disable Syringe With Needle | Single-use product listing |
| Disposable Infusion Set | Includes storage and sterility-handling instructions |
These are current website listings rather than independent laboratory certifications, so specifications should still be checked against the packaging, registration and applicable regulatory documentation for the exact product being purchased.
Why an auto-disable syringe is different—and why its safety mechanism matters
The most consequential part of the Surgi Plast story concerns auto-disable syringes.
An auto-disable syringe is designed with a mechanism that prevents normal reuse after its intended injection. The technology matters particularly in immunization because preventing syringe reuse is a central part of injection safety.
The World Health Organization currently identifies auto-disable syringes as the equipment it strongly recommends for vaccine administration. WHO’s prequalification requirements reference ISO 7886-3, the international standard covering sterile single-use auto-disable syringes for fixed-dose immunization.
WHO also recommends safety-engineered injection devices with reuse-prevention features for applicable therapeutic injections. The underlying purpose is straightforward: a syringe that cannot be reused normally reduces one important pathway for person-to-person transmission of blood-borne infections.
Pakistan has a particular reason to care about that mechanism. WHO research published on therapeutic injections in Pakistan found substantial evidence of syringe reuse and described reuse as a driver of hepatitis C and HIV transmission risk.
That is why a regulatory test of an auto-disable function is not a cosmetic inspection. A failure affects the very feature intended to prevent reuse.
In medical-device reporting, the batch number is often more informative than a brand reputation: it connects a safety notice to identifiable stock.
The 2026 alerts are about specific batches, not every Surgi Plast product
This is the point where precision matters most.
A May 25, 2026 report citing DRAP regulatory alerts stated that two batches of Clinic Auto Disable Syringe 3ml/cc manufactured by Surgi Plast Industries in Gadoon Amazai, Swabi—batch numbers 3-01C-26 and 3-01B-26—were identified as substandard after testing related to the self-destructive or auto-disable function. The report said the wider action involved multiple manufacturers and batches.
A separate June 17, 2026 report by ProPakistani, also citing a DRAP medical-product alert, described another enforcement action involving auto-disable syringes and named one Surgi Plast Clinic Auto Disable Syringe batch among the products affected. That report did not publish the Surgi Plast batch number in the text available for review.
The practical distinction is crucial:
A regulatory action against identified batches is not evidence that every Surgi Plast device is defective.
It would be incorrect to convert a batch-specific finding into a company-wide statement that all Surgi Plast syringes are unsafe. Conversely, the existence of other registered products does not make an affected batch safe. In medical-device safety, the exact product name, size, registration reference and batch number are the decisive identifiers.
Healthcare providers, distributors and procurement teams should therefore compare their physical stock with the latest DRAP notices rather than relying on the company name alone. The regulatory reports themselves directed relevant authorities and supply-chain participants to stop use or distribution of affected stock and pursue recalls.
DRAP’s records show a longer regulatory history than the 2026 headlines suggest
The 2026 alerts did not appear in isolation.
In a 2021 Medical Device Board decision, DRAP recorded SurgiPlast, ELM-0030, with Clinic Auto Disable Syringes in 2ml, 3ml and 5ml, classified as Class B with a five-year shelf life, and the application was approved.
A later DRAP registration dataset shows the company continuing to appear in Pakistan’s registered medical-device records through 2023 and 2025. These entries include different Clinic syringe configurations, the Clinic Blood Transfusion Set and Medi Aqua needles.
DRAP’s 2025 decisions also document applications relating to the company’s manufacturing facilities. The record notes ELM-0030 for syringes and IV sets and separately records approval activity involving a butterfly-needle section and an IV-cannula packing, labelling, sterilization and testing section, with Clinic IV cannula devices listed in Class B. The same record notes that the ELM-0030 license shown there had expired in 2021 and that a renewal application had been submitted; that detail should not be transformed into a claim about the company’s entire present regulatory status without a newer license document.
That caveat is important. Regulatory paperwork can contain historical license states, renewal applications, product registrations and facility approvals at different dates. They should not be collapsed into one simplistic “approved” or “banned” label.
The official website is useful—but it should not be your only verification source
Surgi Plast’s current website does provide useful information. It identifies the factory address, gives telephone numbers, displays syringes and IV products, and continues to show the business online in September 2026.
But the site also contains obvious template inconsistencies. Its testimonial section repeatedly refers to LINEart, a graphic-design business unrelated to medical devices, while its service section displays the placeholder number 123-456-789. Those artifacts do not prove anything about the physical factory or products, but they do show why website content should be cross-checked against regulator records.
For a medical-device manufacturer, the strongest evidence hierarchy is therefore:
- Product and facility information from Pakistan’s regulatory authority.
- Current product labeling and registration information.
- Manufacturer documentation.
- The company’s own website.
- Older commercial directories and supplier profiles.
That hierarchy is especially important when deciding whether an individual medical product can be used or purchased.
A snapshot of the evidence
| Area | Best available evidence |
|---|---|
| Company location | Surgi Plast website + DRAP records |
| Product categories | Surgi Plast website |
| Product registrations | DRAP medical-device registry |
| Establishment facility | DRAP ELM-0030 records |
| 2026 safety alerts | Public reporting citing DRAP alerts |
| Market-share claims | Older supplier directories only; not independently verified |
| Current financial size | No authoritative public figure located |
| Website reliability | Useful for product discovery, but contains visible template inconsistencies |
The Surgi Plast timeline tells a more complicated story than a single recall headline
2006 — Secondary directories date the company’s establishment
PakBD and EC21 list Surgi Plast as established in 2006. Because these are commercial directories rather than primary corporate records, the year should be treated cautiously.
March 16, 2021 — Clinic auto-disable syringes receive DRAP approval
DRAP’s Medical Device Board decision records Clinic Auto Disable Syringes in 2ml, 3ml and 5ml under the SurgiPlast establishment record ELM-0030.
February 21, 2023 — 20ml Clinic disposable syringe registered
DRAP lists Clinic Disposable Syringe 20ml/cc with 21G and 22G needles as MDMR-000227.
December 20, 2023 — Larger syringes and insulin syringe added to the record
DRAP lists 30ml, 50ml and 60ml Clinic Disposable Syringes under MDMR-000307 and a 1cc Clinic insulin syringe under MDMR-000308.
March 3–13, 2025 — Blood-transfusion equipment and needles appear in registrations
The medical-device registry records the Clinic Blood Transfusion Set as MDMR-000487 and Surgi Plast-associated Medi Aqua needles under MDMR-000489 and MDMR-000491.
May 2025 — Additional facility activity appears in DRAP decisions
DRAP records application activity involving Surgi Plast’s IV-cannula and butterfly-needle manufacturing sections. The document also contains historical license-renewal information that should not be mistaken for a current license certificate.
May 2026 — Specific Clinic auto-disable batches face regulatory action
Public reporting citing DRAP identifies 3-01C-26 and 3-01B-26 among Surgi Plast Clinic Auto Disable Syringe 3ml/cc batches declared substandard in connection with the auto-disable/self-destructive performance issue.
June 2026 — Further enforcement reporting keeps the issue active
ProPakistani reported a separate DRAP alert involving a Surgi Plast Clinic Auto Disable Syringe batch as part of a wider action against substandard auto-disable syringes. should actually check
The safest approach is not to ask, “Is Surgi Plast good or bad?”
That question is too broad for a regulated medical device.
The useful questions are much narrower:
What exact product is this?
Check the product name and device type.
What is the registration number?
Compare it with the applicable Pakistani regulatory record.
What is the batch number?
This is essential when checking recalls or safety alerts.
Is the packaging intact?
The company’s own product pages state that sterility may not be guaranteed when packaging is punctured for at least some disposable products.
Is the product being used for its intended purpose?
A syringe designed for one purpose is not automatically suitable for another simply because the volume appears correct.
Is the product currently covered by a regulatory alert?
For recalled or potentially substandard stock, follow the current instructions of DRAP, the healthcare facility and the responsible procurement or pharmacy authority.
WHO’s guidance reinforces the larger principle: safe injection devices are part of infection prevention, and the device’s design, quality and correct disposal all matter.
Frequently Asked Questions About Surgi Plast
What is Surgi Plast?
Surgi Plast is a Pakistani medical-device manufacturer based at Plot 78, Road L4, Industrial Estate Gadoon Amazai, District Swabi, Khyber Pakhtunkhwa. Its public catalogue includes syringes, IV sets, scalp-vein sets and related disposable healthcare products, while DRAP records connect the manufacturer to multiple registered Clinic and Medi Aqua devices.
Where is Surgi Plast located?
Surgi Plast is located in the Gadoon Amazai Industrial Estate in District Swabi, Khyber Pakhtunkhwa, Pakistan. The company website gives Plot 78, Road L4 as its address, and Pakistani regulatory records use the same industrial-estate location for Surgi Plast’s medical-device establishment and registered products.
What products does Surgi Plast make?
Surgi Plast makes or lists disposable medical products including auto-disable syringes, Luer-lock syringes, IV sets, scalp-vein sets and infusion equipment. DRAP records additionally show Clinic Blood Transfusion Sets and Medi Aqua needles associated with the manufacturer. The exact specification should be checked against the product’s current labeling and registration.
Is Surgi Plast regulated in Pakistan?
Surgi Plast appears in Pakistan’s official medical-device regulatory documentation. DRAP records show the establishment reference ELM-0030 and multiple registered products, including Clinic syringes and a Clinic Blood Transfusion Set. However, historical license entries and later facility approvals are not interchangeable, so current procurement decisions should rely on the latest applicable DRAP documents.
Were Surgi Plast syringes recalled in 2026?
Yes, specific Surgi Plast Clinic Auto Disable Syringe batches were identified in 2026 regulatory reporting. A May 2026 report citing DRAP identified batches 3-01C-26 and 3-01B-26 in connection with failures involving the auto-disable or self-destructive function. The finding was batch-specific, not evidence that every Surgi Plast product was recalled.
Should every Surgi Plast product be avoided because of the 2026 alerts?
No such blanket conclusion is supported by the evidence reviewed. The 2026 regulatory actions concerned particular auto-disable syringe products and batches. Other Surgi Plast devices appear separately in DRAP registration records. The responsible approach is to identify the precise product, registration reference and batch number and compare them with current regulatory notices rather than treating the entire brand as one undifferentiated product.
The real Surgi Plast story is about verification, not branding
Surgi Plast has a documented place in Pakistan’s medical-device manufacturing sector. Its Gadoon Amazai, Swabi address appears consistently across company and regulatory records, and DRAP documentation shows a history involving Clinic syringes, IV-related equipment, blood-transfusion sets and needles.
The 2026 safety alerts are important precisely because they are specific. They give investigators, hospitals and distributors something concrete to check: product, size, registration and batch.
That is a much more useful framework than either extreme—declaring every Surgi Plast product unsafe or dismissing regulatory warnings because the company has a long manufacturing history.
The public evidence supports a measured conclusion: Surgi Plast is a real Pakistani medical-device manufacturer with a substantial regulatory footprint, but certain Clinic auto-disable syringe batches received regulatory scrutiny in 2026 and should be evaluated according to the exact batch identifiers and latest DRAP instructions.
Verified outbound sources
- DRAP medical-device registration record
- DRAP establishment-license record
- WHO single-use injection-device guidance
Sources & Verification
- Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) medical-device registration records, including MDMR-000227, MDMR-000307, MDMR-000308, MDMR-000487, MDMR-000489 and MDMR-000491.
- DRAP’s Medical Device Board decisions concerning Clinic auto-disable syringes, blood-transfusion equipment and manufacturing facilities.
- Surgi Plast’s current product and contact pages.
- WHO guidance on auto-disable and safety-engineered injection devices.
- WHO Eastern Mediterranean research on syringe reuse and injection safety in Pakistan.
- 2026 public reporting citing DRAP alerts concerning specific Surgi Plast Clinic auto-disable syringe batches.
- Older commercial directories used only to assess historical establishment and market-share claims; those claims were not treated as authoritative.
Editorial Disclaimer: This article is for informational and journalistic purposes and does not replace product-specific regulatory instructions, clinical judgment or professional medical advice. Medical-device status can change through new registrations, recalls, enforcement actions or updated notices. Readers handling Surgi Plast products should verify the exact product, registration and batch information against the latest DRAP guidance before use or procurement.
